Literature DB >> 29536324

Comparison between multifocal ERG and C-Scan SD-OCT ("en face" OCT) in patients with a suspicion of antimalarial retinal toxicity: preliminary results.

Carl Arndt1, Mathieu Costantini2, Christophe Chiquet3, Mickael Afriat2, Sylvie Berthemy3, Vivien Vasseur4, Alain Ducasse2, Martine Mauget-Faÿsse4.   

Abstract

PURPOSE: Pericentral visual field changes and disruption of the ellipsoid layer on spectral domain optical coherence tomography (SD-OCT) are the main features of antimalarial retinal toxicity. C-Scan OCT or "en face" enables a topographic frontal view of the changes observed within the different retinal layers in particular the ellipsoid layer. The aim of this prospective study was to compare multifocal ERG (mfERG) responses with the results of C-Scan OCT ("en face" OCT) in patients with abnormal visual field and to analyze relationships between the structural and functional abnormalities.
METHODS: In 354 consecutive patients screened for antimalarial toxicity between January 1, 2014 and December 31, 2016, central visual field, mfERG recording, C-Scan OCT and short-wavelength fundus autofluorescent imaging were performed.
RESULTS: Among the 17/354 patients with abnormal central visual field results, all presented with abnormalities on the mfERG at least in one eye. In 16/33 eyes, there was a good concordance between focal loss of the mfERG response and the disruption of the ellipsoid layer on C-Scan OCT. In one eye with characteristic changes in the ellipsoid layer on the C-Scan OCT, the mfERG was normal, whereas in three eyes the mfERG was abnormal in eyes with a normal C-Scan OCT.
CONCLUSIONS: The contribution of the C-Scan OCT changes remains difficult to establish as there is no strict concordance with the local ERG responses. Although C-Scan OCT technology provides a new approach in analyzing focal abnormalities in the photoreceptor-retinal pigment epithelium interface, the sensitivity of this method compared with mfERG and other tests (central visual field, B-Scan OCT) needs to be evaluated. This study is still ongoing on a larger cohort.

Entities:  

Keywords:  En face OCT; Hydroxychloroquine retinopathy; Multifocal electroretinogram; Optical coherence tomography; Ring ratio

Mesh:

Substances:

Year:  2018        PMID: 29536324     DOI: 10.1007/s10633-018-9625-2

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN: 0012-4486            Impact factor:   2.379


  10 in total

1.  Fundus autofluorescence and mfERG for early detection of retinal alterations in patients using chloroquine/hydroxychloroquine.

Authors:  Ulrich Kellner; Agnes B Renner; Hilmar Tillack
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-08       Impact factor: 4.799

Review 2.  Antimalarial drugs in the treatment of rheumatological diseases.

Authors:  R I Rynes
Journal:  Br J Rheumatol       Date:  1997-07

Review 3.  Hydroxychloroquine and chloroquine retinopathy: a systematic review evaluating the multifocal electroretinogram as a screening test.

Authors:  Adrian C Tsang; Sina Ahmadi Pirshahid; Gianni Virgili; Chloe C Gottlieb; John Hamilton; Stuart G Coupland
Journal:  Ophthalmology       Date:  2015-03-29       Impact factor: 12.079

4.  The Demise of the Bull's Eye (Screening for Hydroxychloroquine Retinopathy).

Authors:  Michael F Marmor
Journal:  Retina       Date:  2016-10       Impact factor: 4.256

5.  Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy.

Authors:  Michael F Marmor; Ulrich Kellner; Timothy Y Y Lai; Jonathan S Lyons; William F Mieler
Journal:  Ophthalmology       Date:  2011-02       Impact factor: 12.079

6.  [Ophthalmological monitoring protocol for patients treated with long-term antimalarials or vigabatrin].

Authors:  I Ingster-Moati; C Orssaud
Journal:  J Fr Ophtalmol       Date:  2009-02-04       Impact factor: 0.818

7.  Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).

Authors:  Michael F Marmor; Ulrich Kellner; Timothy Y Y Lai; Ronald B Melles; William F Mieler
Journal:  Ophthalmology       Date:  2016-03-16       Impact factor: 12.079

8.  Long-term course of chloroquine retinopathy after cessation of medication.

Authors:  J R Brinkley; E L Dubois; S J Ryan
Journal:  Am J Ophthalmol       Date:  1979-07       Impact factor: 5.258

9.  Assessment of hydroxychloroquine maculopathy after cessation of treatment: an optical coherence tomography and multifocal electroretinography study.

Authors:  Marilita M Moschos; Eirini Nitoda; Irini P Chatziralli; Zisis Gatzioufas; Chryssanthi Koutsandrea; George Kitsos
Journal:  Drug Des Devel Ther       Date:  2015-06-11       Impact factor: 4.162

10.  Relative sensitivity and specificity of 10-2 visual fields, multifocal electroretinography, and spectral domain optical coherence tomography in detecting hydroxychloroquine and chloroquine retinopathy.

Authors:  David J Browning; Chong Lee
Journal:  Clin Ophthalmol       Date:  2014-07-25
  10 in total
  4 in total

Review 1.  [Progressive maculopathy despite discontinuation of chloroquine treatment-multimodal imaging and review of the literature].

Authors:  A Rickmann; S Al-Nawaiseh; L Ramirez; S Röhrig; M Ladewig; P Szurman; G Szurman
Journal:  Ophthalmologe       Date:  2020-09       Impact factor: 1.059

2.  Identification of clusters in multifocal electrophysiology recordings to maximize discriminant capacity (patients vs. control subjects).

Authors:  M Ortiz Del Castillo; B Cordón; E M Sánchez Morla; E Vilades; M J Rodrigo; C Cavaliere; L Boquete; E Garcia-Martin
Journal:  Doc Ophthalmol       Date:  2019-09-19       Impact factor: 2.379

3.  Risk factors for hydroxychloroquine retinopathy in systemic lupus erythematosus: a case-control study with hydroxychloroquine blood-level analysis.

Authors:  Tiphaine Lenfant; Sawsen Salah; Gaëlle Leroux; Elodie Bousquet; Véronique Le Guern; François Chasset; Camille Francès; Nathalie Morel; Julie Chezel; Thomas Papo; Patrice Cacoub; Luc Mouthon; Gaëlle Guettrot-Imbert; Pascal Cohen; Alexis Régent; Martine Mauget-Faÿsse; Jean-Charles Piette; Moez Jallouli; Nathalie Costedoat-Chalumeau
Journal:  Rheumatology (Oxford)       Date:  2020-12-01       Impact factor: 7.580

Review 4.  An overview of the safety assessment of medicines currently used in the COVID-19 disease treatment.

Authors:  Dragana Javorac; Lazar Grahovac; Luka Manić; Nikola Stojilković; Milena Anđelković; Zorica Bulat; Danijela Đukić-Ćosić; Marijana Curcic; Aleksandra Buha Djordjevic
Journal:  Food Chem Toxicol       Date:  2020-07-21       Impact factor: 6.023

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.